Relationship between the Finnish Diabetes Risk Score, fasting blood glucose and glycohemoglobin A1c

Authors

  • María Zulema Chaila Center for Clinical and Specialized Analysis (CACE), San Miguel de Tucumán, Tucumán, Argentina
  • Matías Viniegra Zanuso Viniegra Laboratory (VZ), Autonomous City of Buenos Aires, Argentina
  • Juan José Gagliardino National University of La Plata-National Council for Scientific and Technical Research (UNLP-CONICET), Faculty of Medical Sciences, La Plata, Province of Buenos Aires, Argentina
  • Carla Lucarelli IACA Laboratories, Bahía Blanca, Province of Buenos Aires, Argentina
  • Gustavo Maccallini Hidalgo Laboratory, Martínez, Province of Buenos Aires, Argentina
  • Mauro Frusti Baires Lab, Autonomous City of Buenos Aires, Argentina
  • Osvaldo Elbarcha LACE S.A. Laboratory, Córdoba, Argentina
  • Adrián Aymard Laboratory TCba Diagnostic Center, Autonomous City of Buenos Aires, Argentina
  • Pablo Salgado University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Carlos Javier Buso María Curie Nunicipal Oncology Hospital, Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina
  • Claudio Daniel González Austral and Favaloro Universities and the Norberto Quirno Medical Education and Clinical Research University Institute (CEMIC) of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Víctor Francisco Commendatore National Northeast University (UNNE), Faculty of Medicine, Corrientes, Argentina

DOI:

https://doi.org/10.47196/diab.v57i2.624

Keywords:

finnish diabetes risk score, impaired fasting blood glucosa, HbA1c, prediabetes, diabetes mellitus

Abstract

Introduction: the Finnish Diabetes Risk Score (FINDRISC) has high sensitivity and specificity for the identification of people at risk of diabetes mellitus (DM) in various populations. Therefore, we aimed to use this index to identify individuals at risk of having alterations in fasting glycemia (FG) and HbA1c. among those who underwent laboratory analysis at ALAC, Argentina.

Objectives: to explore the relationships of the FINDRISC score with the fasting blood glucose (FG) concentration and glycated hemoglobin (HbA1c) level, and to establish appropriate cut-off scores to predict FG ≥100 mg/dL and HbA1c ≥ 5.7% (38.8 mmol/mol) in this population.

Material an methods: we recruited 1,175 individuals from 45 ALAC laboratories for whom FG and HbA1c had been measured. We analyzed the data using the chi square test, odds ratios, ANOVA plus Tukey’s post-hoc test, binomial logistic regression, and receiver operating characteristic (ROC) curves.

Results: total FINDRISC score significantly positively correlated with both FG and HbA1c. Of the constituent variables, age ≥45 years, a large waist circumference, a body mass index ≥25 kg/m2, a close family history of DM, and the use of antihypertensive medication were significantly associated with FG ≥100 mg/dL and/or HbA1c ≥5.7% (38.8 mmol/mol). However, no significant association was found with physical activity or the daily consumption of fruit and vegetables. The mean FG and HbA1c for individuals with total FINDRISC scores ≤11 were 89.9 mg/dL and 5.2% (33.0 mmol/mol), respectively, which increased to 116.1 mg/dL and 6.1% (43.0 mmol/mol) for individuals with scores ≥21, with a dose/response-type relationship. ROC analysis showed that a FINDRISC of 13 was associated with a sensitivity of 81.89%, a specificity of 67.60%, and a correct diagnosis rate of 70.55% for HbA1c ≥5.7% (38.8 mmol/mol); and a sensitivity of 72.50%, a specificity of 70.62%, and a correct diagnosis rate of 71.20% for FG ≥100 mg/dL.

Conclusions: FINDRISC score increases with increasing FG and HbA1c, and is a useful means of identifying people with FG ≥100 mg/dL and HbA1c ≥5.7% (38.8 mmol/mol).

Author Biographies

María Zulema Chaila, Center for Clinical and Specialized Analysis (CACE), San Miguel de Tucumán, Tucumán, Argentina

Biochemistry, on behalf of the study group of the Association of High Complexity Laboratories, ALAC

 

Matías Viniegra, Zanuso Viniegra Laboratory (VZ), Autonomous City of Buenos Aires, Argentina

Biochemist, on behalf of the study group of the Association of High Complexity Laboratories, ALAC

Juan José Gagliardino, National University of La Plata-National Council for Scientific and Technical Research (UNLP-CONICET), Faculty of Medical Sciences, La Plata, Province of Buenos Aires, Argentina

Biochemist

Carla Lucarelli, IACA Laboratories, Bahía Blanca, Province of Buenos Aires, Argentina

Biochemistry, Association of High Complexity Laboratories (ALAC)

Gustavo Maccallini, Hidalgo Laboratory, Martínez, Province of Buenos Aires, Argentina

Biochemist, on behalf of the study group of the Association of High Complexity Laboratories, ALAC

Mauro Frusti, Baires Lab, Autonomous City of Buenos Aires, Argentina

Biochemist, Technical Director

Osvaldo Elbarcha, LACE S.A. Laboratory, Córdoba, Argentina

Biochemist, on behalf of the study group of the Association of High Complexity Laboratories, ALAC

Adrián Aymard, Laboratory TCba Diagnostic Center, Autonomous City of Buenos Aires, Argentina

Biochemist, on behalf of the study group of the Association of High Complexity Laboratories, ALAC

Pablo Salgado, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Biologist, Public Health Research Institute

Carlos Javier Buso, María Curie Nunicipal Oncology Hospital, Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina

Coordinator of the Nutrition and Diabetes Working Group

Claudio Daniel González, Austral and Favaloro Universities and the Norberto Quirno Medical Education and Clinical Research University Institute (CEMIC) of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Associate Professor of Pharmacology, Argentine Diabetes Society (SAD)

Víctor Francisco Commendatore, National Northeast University (UNNE), Faculty of Medicine, Corrientes, Argentina

Director of the Master's Program in Diabetes, Argentine Diabetes Society (SAD)

References

I. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119.

II. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021 Jan;44(Suppl 1):S125-S150. doi: 10.2337/dc21-S010. Erratum in: Diabetes Care 2021 Sep;44(9):2183-2185.

III. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003 Mar;26(3):725-31. doi: 10.2337/diacare.26.3.725.

IV. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017 Mar 16;14:E24. doi: 10.5888/pcd14.160287.

V. Tuomilehto J, Lindström J, Hellmich M, Lehmacher W, Westermeier T, Evers T, Brückner A, Peltonen M, Qiao Q, Chiasson JL. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus. The STOP-NIDDM risk-score. Diabetes Res Clin Pract 2010 Feb;87(2):267-74. doi: 10.1016/j.diabres.2009.11.011.

VI. Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009 Feb;41(2):86-97. doi: 10.1055/s-0028-1087203.

VII. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021 Jan;44(Suppl 1):S15-S33. doi: 10.2337/dc21-S002. Erratum in: Diabetes Care 2021 Sep;44(9):2182.

VIII. Pesaro AE, Bittencourt MS, Franken M, Carvalho JAM, Bernardes D, Tuomilehto J, Santos RD. The Finnish Diabetes Risk Score (FINDRISC), incident diabetes and low-grade inflammation. Diabetes Res Clin Pract 2021 Jan;171:108558. doi: 10.1016/j.diabres.2020.108558.

IX. Bernabe-Ortiz A, Perel P, Miranda JJ, Smeeth L. Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population. Prim Care Diabetes 2018 Dec;12(6):517-525. doi: 10.1016/j.pcd.2018.07.015.

X. Rodríguez MG, Saldaña MR, Leyva JMA, Rojas RM, Molina-Recio G. The FINDRISC questionnaire capacity to predict diabetes mellitus II, arterial hypertension and comorbidity in women from low-and-middle-income countries. Health Care Women Int 2020 Feb;41(2):205-226. doi: 10.1080/07399332.2019.1680678.

XI. López-González AA, García-Agudo S, Tomás-Salvá M, Vicente-Herrero MT, Queimadelos-Carmona M, Campos-González I. Test FINDRISC: relación con parámetros y escalas de riesgo cardiovascular en población mediterránea española. Rev Med Inst Mex Seguro Soc 2017 May-Jun;55(3):309-316.

XII. Lima-Martínez MM, Colmenares L, Campanelli Y, Paoli M, Rodney M, Santos RD, Iacobellis G. Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America. Clin Investig Arterioscler 2019 Jan-Feb;31(1):15-22. English, Spanish. doi: 10.1016/j.arteri.2018.06.002.

XIII. Carvalho JA, Barengo NC, Tuomilehto J, Conceição RD, Santos RD. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Ann Med 2011;43(6):487-94. doi: 10.3109/07853890.2011.554428. Epub 2011 May 23.

XIV. Hellgren MI, Petzold M, Björkelund C, Wedel H, Jansson PA, Lindblad U. Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study. Diabet Med 2012 Dec;29(12):1501-5. doi: 10.1111/j.1464-5491.2012.03664.x..

XV. Gagliardino J, et al. Prevención primaria de diabetes tipo 2 en Argentina: estudio piloto en la provincia de Buenos Aires. Rev Arg Endocr MEtab 2016;53(4):135-141.

XVI. Guzmán-Rodríguez S, et al. Estudio de detección de riesgo de DM en atención primaria según cuestionario FINDRISC en el municipio de General Pueyrredón. Rev Soc Arg Diab 2016;50(3):96-107.

Published

2023-06-26

How to Cite

Chaila, M. Z., Viniegra, M., Gagliardino, J. J., Lucarelli, C., Maccallini, G., Frusti, M., Elbarcha, O., Aymard, A., Salgado, P., Buso, C. J., González, C. D., & Commendatore, V. F. (2023). Relationship between the Finnish Diabetes Risk Score, fasting blood glucose and glycohemoglobin A1c. Journal of the Argentine Society of Diabetes, 57(2), 75–83. https://doi.org/10.47196/diab.v57i2.624

Issue

Section

Original article

Most read articles by the same author(s)

<< < 1 2 3 4 5